EVA1-antibody drug conjugate is a new therapeutic strategy for eliminating glioblastoma-initiating cells.

ABSTRACT:

Background

The discovery of glioblastoma (GBM)-initiating cells (GICs) has impacted GBM research. These cells are not only tumorigenic but also exhibit resistance to radiotherapy and chemotherapy. Therefore, it is crucial to characterize GICs thoroughly and identify new therapeutic targets. In a previous study, we successfully identified epithelial-V-like antigen 1 (EVA1) as a novel functional factor specific to GICs.

Methods

Hybridoma cells were generated by immunizing BALB/c mice with EVA1-Fc fusion protein. The reactivity of the supernatant from these hybridoma cells was examined using EVA1-overexpressing cells and GICs. Candidate antibodies were further selected using Biacore surface plasmon resonance analysis and 2 cytotoxicity assays-antibody-dependent cell cytotoxicit

SUBMITTER: Hou J 

PROVIDER: S-EPMC11889714 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature